PT2931265T - Péptidos axl modificados e sua utilização na inibição da sinalização de axl em terapêutica anti-metastática - Google Patents

Péptidos axl modificados e sua utilização na inibição da sinalização de axl em terapêutica anti-metastática

Info

Publication number: PT2931265T
Authority: PT; Portugal
Prior art keywords: axl; inhibition; modified; peptides; signaling
Prior art date: 2012-12-14

Application number

PT138627807T

Other languages

English (en)

Inventor

Bruno Rankin Erinn

r cochran Jennifer

J Giaccia Amato

Jones Douglas

Kariolis Mihalis

Fuh Katherine

Miao Yu

Hershenson Susan

Original Assignee

Univ Leland Stanford Junior

Aravive Biologics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-12-14

Filing date

2013-12-12

Publication date

2018-04-16

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50934967&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2931265(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-12-12 Application filed by Univ Leland Stanford Junior, Aravive Biologics Inc filed Critical Univ Leland Stanford Junior

2018-04-16 Publication of PT2931265T publication Critical patent/PT2931265T/pt

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/10—Protein-tyrosine kinases (2.7.10)
- C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)

PT138627807T 2012-12-14 2013-12-12 Péptidos axl modificados e sua utilização na inibição da sinalização de axl em terapêutica anti-metastática PT2931265T (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201261737276P	2012-12-14	2012-12-14

Publications (1)

Publication Number	Publication Date
PT2931265T true PT2931265T (pt)	2018-04-16

Family

ID=50934967

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PT171966625T PT3326622T (pt)	2012-12-14	2013-12-12	Péptidos axl modificados e sua utilização na inibição da sinalização de axl em terapêutica anti-metastática
PT138627807T PT2931265T (pt)	2012-12-14	2013-12-12	Péptidos axl modificados e sua utilização na inibição da sinalização de axl em terapêutica anti-metastática

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PT171966625T PT3326622T (pt)	2012-12-14	2013-12-12	Péptidos axl modificados e sua utilização na inibição da sinalização de axl em terapêutica anti-metastática

Country Status (12)

Country	Link
US (3)	US9822347B2 (pt)
EP (2)	EP2931265B3 (pt)
JP (2)	JP6345690B2 (pt)
AU (3)	AU2013359179B2 (pt)
CA (1)	CA2894539C (pt)
DK (2)	DK2931265T6 (pt)
ES (2)	ES2665323T7 (pt)
FI (1)	FI2931265T6 (pt)
HK (1)	HK1256071A1 (pt)
NO (1)	NO3049208T3 (pt)
PT (2)	PT3326622T (pt)
WO (1)	WO2014093690A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9074192B2 (en) *	2010-01-22	2015-07-07	The Board Of Trustees Of The Leland Stanford Junior University	Inhibition of AXL signaling in anti-metastatic therapy
CA3056999A1 (en) *	2010-01-22	2011-07-28	Amato J. Giaccia	Inhibition of axl signaling in anti-metastatic therapy
WO2013090776A1 (en)	2011-12-15	2013-06-20	The Board Of Trustees Of The Leland Stanford Junior University	Inhibition of axl/gas6 signaling in the treatment of disease
FI2931265T6 (fi)	2012-12-14	2023-05-23		Muokattuja axl-peptidejä ja niiden käyttö axl-viestinvälityksen estossa etäispesäkkeitä estävässä hoidossa
US10137173B2 (en)	2014-10-20	2018-11-27	Aravive Biologics, Inc.	Antiviral activity of Gas6 inhibitor
ES2834618T3 (es) *	2014-12-18	2021-06-18	Aravive Biologics Inc	Actividad antifibrótica del inhibidor de GAS6
AU2018359863A1 (en) *	2017-11-04	2020-07-02	Aravive Biologics, Inc	Methods of treating metastatic cancers using axl decoy receptors

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4458066A (en)	1980-02-29	1984-07-03	University Patents, Inc.	Process for preparing polynucleotides
EP0394827A1 (en)	1989-04-26	1990-10-31	F. Hoffmann-La Roche Ag	Chimaeric CD4-immunoglobulin polypeptides
US5538861A (en)	1994-07-29	1996-07-23	Amgen Inc.	DNA encoding a stimulating factor for the axl receptor
US20030032103A1 (en)	1997-09-18	2003-02-13	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6737056B1 (en) *	1999-01-15	2004-05-18	Genentech, Inc.	Polypeptide variants with altered effector function
EP1382969A1 (en)	2002-07-17	2004-01-21	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Diagnosis and prevention of cancer cell invasion
AU2003304180A1 (en)	2002-09-24	2005-01-04	Dow, Kenneth, Centocor, Inc.	Growth arrest specific gene 6 peptides, antibodies, compositions, methods and uses
MXPA05011171A (es)	2003-04-18	2005-12-14	Novartis Ag	Metodos y composiciones que activan cinasas de tirosina para el diagnostico y tratamiento de osteoartritis.
JP2005278631A (ja)	2004-03-04	2005-10-13	National Institute Of Advanced Industrial & Technology	Ａｘｌリガンド結合領域蛋白質、その製造方法及びそれを用いたスクリーニング方法
US20080267975A1 (en)	2004-11-24	2008-10-30	The Regents Of The University Of Colorado	Mer Diagnostic and Therapeutic Agents
EP2177614B1 (en)	2005-05-02	2014-12-31	Toray Industries, Inc.	Composition and method for diagnosing esophageal cancer and metastasis of esophageal cancer
WO2008098139A2 (en)	2007-02-07	2008-08-14	The Regents Of The University Of Colorado	Axl tyrosine kinase inhibitors and methods of making and using the same
US7998966B2 (en)	2007-04-13	2011-08-16	Supergen, Inc.	Axl kinase inhibitors
EP2170395A1 (en)	2007-07-02	2010-04-07	Wyeth LLC	Modulators of axl for use in treating bone disorders
WO2010014755A1 (en) *	2008-07-29	2010-02-04	The Regents Of The University Of Colorado	Methods and compounds for enhancing anti-cancer therapy
AU2009327058A1 (en) *	2008-12-19	2011-06-30	Novartis Ag	Soluble polypeptides for use in treating autoimmune and inflammatory disorders
KR20120035145A (ko) *	2009-05-11	2012-04-13	우드라이 파마 게엠베하	인간화 ａｘｌ 항체
CA3056999A1 (en)	2010-01-22	2011-07-28	Amato J. Giaccia	Inhibition of axl signaling in anti-metastatic therapy
US9074192B2 (en)	2010-01-22	2015-07-07	The Board Of Trustees Of The Leland Stanford Junior University	Inhibition of AXL signaling in anti-metastatic therapy
JP6170435B2 (ja)	2010-11-08	2017-07-26	ザボードオブトラスティーズオブザレランドスタンフォードジュニアユニバーシティー	改変ノッチンペプチドを含む融合タンパク質及びその使用
WO2013090776A1 (en)	2011-12-15	2013-06-20	The Board Of Trustees Of The Leland Stanford Junior University	Inhibition of axl/gas6 signaling in the treatment of disease
WO2014093707A1 (en)	2012-12-14	2014-06-19	The Board Of Trustees Of The Leland Stanford Junior University	Inhibition of axl signaling in primary tumor therapy
FI2931265T6 (fi)	2012-12-14	2023-05-23		Muokattuja axl-peptidejä ja niiden käyttö axl-viestinvälityksen estossa etäispesäkkeitä estävässä hoidossa
WO2015030849A1 (en) *	2013-08-30	2015-03-05	The Board Of Trustees Of The Leland Stanford Junior University	High-affinity binding to gas6
ES2834618T3 (es) *	2014-12-18	2021-06-18	Aravive Biologics Inc	Actividad antifibrótica del inhibidor de GAS6

2013
- 2013-12-12 FI FIEP13862780.7T patent/FI2931265T6/fi active
- 2013-12-12 ES ES13862780T patent/ES2665323T7/es active Active
- 2013-12-12 JP JP2015547567A patent/JP6345690B2/ja active Active
- 2013-12-12 EP EP13862780.7A patent/EP2931265B3/en active Active
- 2013-12-12 DK DK13862780.7T patent/DK2931265T6/da active
- 2013-12-12 CA CA2894539A patent/CA2894539C/en active Active
- 2013-12-12 EP EP17196662.5A patent/EP3326622B1/en active Active
- 2013-12-12 US US14/650,854 patent/US9822347B2/en active Active
- 2013-12-12 PT PT171966625T patent/PT3326622T/pt unknown
- 2013-12-12 DK DK17196662.5T patent/DK3326622T3/da active
- 2013-12-12 AU AU2013359179A patent/AU2013359179B2/en active Active
- 2013-12-12 PT PT138627807T patent/PT2931265T/pt unknown
- 2013-12-12 WO PCT/US2013/074786 patent/WO2014093690A1/en active Application Filing
- 2013-12-12 ES ES17196662T patent/ES2862335T3/es active Active
2014
- 2014-06-30 NO NO14741534A patent/NO3049208T3/no unknown
2017
- 2017-10-13 US US15/783,850 patent/US11136563B2/en active Active
- 2017-12-06 AU AU2017272193A patent/AU2017272193A1/en not_active Abandoned
2018
- 2018-05-23 JP JP2018098435A patent/JP6832887B2/ja active Active
- 2018-11-27 HK HK18115132.7A patent/HK1256071A1/zh unknown
2019
- 2019-08-02 AU AU2019210662A patent/AU2019210662B2/en active Active
2021
- 2021-09-02 US US17/465,203 patent/US20220220458A1/en active Pending

Also Published As

Publication number	Publication date
WO2014093690A1 (en)	2014-06-19
US20180030422A1 (en)	2018-02-01
US20150315553A1 (en)	2015-11-05
EP3326622B1 (en)	2021-01-20
US9822347B2 (en)	2017-11-21
EP2931265A1 (en)	2015-10-21
EP3326622A1 (en)	2018-05-30
ES2665323T7 (es)	2023-06-15
AU2013359179A1 (en)	2015-07-02
JP2018154641A (ja)	2018-10-04
AU2017272193A1 (en)	2017-12-21
CA2894539C (en)	2021-09-28
NO3049208T3 (pt)	2018-04-14
JP6345690B2 (ja)	2018-06-20
AU2013359179B2 (en)	2017-10-05
US20220220458A1 (en)	2022-07-14
ES2862335T3 (es)	2021-10-07
JP2016510309A (ja)	2016-04-07
AU2019210662A1 (en)	2019-08-22
US11136563B2 (en)	2021-10-05
EP2931265B3 (en)	2023-04-05
CA2894539A1 (en)	2014-06-19
JP6832887B2 (ja)	2021-02-24
HK1256071A1 (zh)	2019-09-13
FI2931265T6 (fi)	2023-05-23
AU2019210662B2 (en)	2021-07-01
DK3326622T3 (da)	2021-04-06
DK2931265T6 (da)	2023-05-01
ES2665323T3 (es)	2018-04-25
PT3326622T (pt)	2021-04-07
DK2931265T3 (en)	2018-04-16
EP2931265B1 (en)	2018-01-31
EP2931265A4 (en)	2016-08-31

Publication	Publication Date	Title
HK1245806A1 (zh)	2018-08-31	抗轉移療法中axl信號傳導的抑制
HK1256071A1 (zh)	2019-09-13	改性axl肽及其在抗轉移治療中抑制axl信號傳導的應用
EP2831001A4 (en)	2016-04-27	COMPOSITION FOR THE TREATMENT OF WATER AND METHOD FOR USE
EP2912178A4 (en)	2016-05-25	SUPER AMPLIFIER AND METHOD FOR USE THEREOF
ZA201307797B (en)	2019-02-27	Bicyclic heterocycle compounds and their uses in therapy
ZA201405858B (en)	2016-08-31	Recombinant microorganisms and methods of use thereof
GB201218862D0 (en)	2012-12-05	Bicyclic heterocycle compounds and their uses in therapy
GB201218850D0 (en)	2012-12-05	Bicyclic heterocycle compounds and their uses in therapy
EP2906700A4 (en)	2016-08-31	GENETICALLY ENCODED CALCIUM INDICATORS AND METHODS OF USE
GB201218864D0 (en)	2012-12-05	Bicyclic heterocycle compounds and their uses in therapy
HK1203842A1 (en)	2015-11-06	Maesa japonica extracts and methods of use
EP2806811A4 (en)	2016-05-18	VERTEBRAL CONSTRUCTION
HK1204772A1 (en)	2015-12-04	Aromatic-cationic peptides and uses of same
EP2852397A4 (en)	2016-03-23	HUWENTOXIN IV VARIANTS AND METHODS OF USE
HK1207953A1 (en)	2016-02-19	An enhanced therapeutic stimulus system and methods of use
PL2790666T3 (pl)	2017-12-29	Ekstrakty z maesa japonica i sposoby zastosowania
HK1209639A1 (en)	2016-04-08	Gpbp-1 inhibition and its therapeutic use gpbp-1
HK1247087A1 (zh)	2018-09-21	草藥補充劑及其使用方法
PL2667880T3 (pl)	2017-07-31	Oligopeptydy metaloproteinaz i ich zastosowanie terapeutyczne
EP2934543A4 (en)	2016-06-22	STIMULATION AND INCREASE IN TISSUE REGENERATION
GB201219678D0 (en)	2012-12-12	Ketone body inhibitors and uses thereof
EP2744786A4 (en)	2015-01-07	SUBSTITUTED 2-IMIDAZOLIDINONE AND 2-IMIDAZOLONE AND THEIR USE IN THE TREATMENT OF CANCER
HK1206977A1 (en)	2016-01-22	Aromatic-cationic peptides and uses of same
ZA201408128B (en)	2015-12-23	Etract of greyia radlkoferi and use thereof
EP2817004A4 (en)	2015-07-22	BOUVARDIN DERIVATIVES AND THEIR THERAPEUTIC USES